Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317568496> ?p ?o ?g. }
- W4317568496 endingPage "67" @default.
- W4317568496 startingPage "53" @default.
- W4317568496 abstract "Introduction Acute myeloid leukemia (AML) is a heterogeneous disease characterized by many cytogenetic and molecular alterations. Due to better knowledge of the molecular basis of AML, many targeted therapies have been introduced and registered, e.g. FMS-like tyrosine kinase 3 inhibitors, isocitrate dehydrogenase 1/2 mutation inhibitors, and Bcl-2 inhibitor. Despite that, the cure for AML remains an unmet clinical need in most patients.Areas covered The review aims to present new, not yet registered drugs for AML. We searched the English literature for articles concerning AML, targeted drugs, menin inhibitors, DOT1L, BET, IDH inhibitors, FLT3, hedgehog inhibitors, Polo-like kinase inhibitors, RNA splicing, and immune therapies via PubMed. Publications from January 2000 to August 2022 were scrutinized. Additional relevant publications were obtained by reviewing the references from the chosen articles and Google search. Conference proceedings from the previous 5 years of The American Society of Hematology, the European Hematology Association, and the American Society of Clinical Oncology were searched manually. Additional relevant publications were obtained by reviewing the references.Expert opinion For several years, the therapeutic approach in AML has become more individualized. Novel groups of drugs give hope for greater curability. High response rates have agents that restore the activity of the p53 protein. In addition, agents that work independently of a particular mutation seem promising for AML without any known mutation." @default.
- W4317568496 created "2023-01-21" @default.
- W4317568496 creator A5064484491 @default.
- W4317568496 creator A5068357792 @default.
- W4317568496 creator A5087571749 @default.
- W4317568496 date "2023-01-02" @default.
- W4317568496 modified "2023-09-27" @default.
- W4317568496 title "Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities" @default.
- W4317568496 cites W1592021885 @default.
- W4317568496 cites W1600365609 @default.
- W4317568496 cites W1812256879 @default.
- W4317568496 cites W1983973479 @default.
- W4317568496 cites W2001854096 @default.
- W4317568496 cites W2020197807 @default.
- W4317568496 cites W2020203596 @default.
- W4317568496 cites W2021970502 @default.
- W4317568496 cites W2026826794 @default.
- W4317568496 cites W2044088883 @default.
- W4317568496 cites W2046540572 @default.
- W4317568496 cites W2046978891 @default.
- W4317568496 cites W2048860841 @default.
- W4317568496 cites W2055884944 @default.
- W4317568496 cites W2058153393 @default.
- W4317568496 cites W2058624670 @default.
- W4317568496 cites W2066640259 @default.
- W4317568496 cites W2069918359 @default.
- W4317568496 cites W2073889874 @default.
- W4317568496 cites W2077057971 @default.
- W4317568496 cites W2089881927 @default.
- W4317568496 cites W2091208410 @default.
- W4317568496 cites W2098058376 @default.
- W4317568496 cites W2101725260 @default.
- W4317568496 cites W2117499535 @default.
- W4317568496 cites W2124513722 @default.
- W4317568496 cites W2127132803 @default.
- W4317568496 cites W2127568389 @default.
- W4317568496 cites W2129129812 @default.
- W4317568496 cites W2137881702 @default.
- W4317568496 cites W2140231410 @default.
- W4317568496 cites W2140364596 @default.
- W4317568496 cites W2140419897 @default.
- W4317568496 cites W2144672860 @default.
- W4317568496 cites W2150056778 @default.
- W4317568496 cites W2151718828 @default.
- W4317568496 cites W2153994826 @default.
- W4317568496 cites W2155106329 @default.
- W4317568496 cites W2167831982 @default.
- W4317568496 cites W2299219969 @default.
- W4317568496 cites W2413340136 @default.
- W4317568496 cites W2419140434 @default.
- W4317568496 cites W2475371777 @default.
- W4317568496 cites W2476685579 @default.
- W4317568496 cites W2502718344 @default.
- W4317568496 cites W2555124596 @default.
- W4317568496 cites W2593059553 @default.
- W4317568496 cites W2596064219 @default.
- W4317568496 cites W2623089849 @default.
- W4317568496 cites W2715749014 @default.
- W4317568496 cites W2790209799 @default.
- W4317568496 cites W2800912743 @default.
- W4317568496 cites W2802129476 @default.
- W4317568496 cites W2802288784 @default.
- W4317568496 cites W2883936808 @default.
- W4317568496 cites W2891237423 @default.
- W4317568496 cites W2891324443 @default.
- W4317568496 cites W2891826418 @default.
- W4317568496 cites W2900410545 @default.
- W4317568496 cites W2902234853 @default.
- W4317568496 cites W2903041954 @default.
- W4317568496 cites W2905340197 @default.
- W4317568496 cites W2912893146 @default.
- W4317568496 cites W2913271650 @default.
- W4317568496 cites W2913322626 @default.
- W4317568496 cites W2937725692 @default.
- W4317568496 cites W2939577741 @default.
- W4317568496 cites W2944553601 @default.
- W4317568496 cites W2945338000 @default.
- W4317568496 cites W2948900598 @default.
- W4317568496 cites W2955608015 @default.
- W4317568496 cites W2965551559 @default.
- W4317568496 cites W2972868802 @default.
- W4317568496 cites W2982353618 @default.
- W4317568496 cites W2983543368 @default.
- W4317568496 cites W2987081466 @default.
- W4317568496 cites W2989871594 @default.
- W4317568496 cites W2990466539 @default.
- W4317568496 cites W2990749880 @default.
- W4317568496 cites W2993435749 @default.
- W4317568496 cites W2995123606 @default.
- W4317568496 cites W3001216252 @default.
- W4317568496 cites W3002439510 @default.
- W4317568496 cites W3004043543 @default.
- W4317568496 cites W3012293314 @default.
- W4317568496 cites W3014928753 @default.
- W4317568496 cites W3024512534 @default.
- W4317568496 cites W3028372384 @default.
- W4317568496 cites W3030216611 @default.
- W4317568496 cites W3046762554 @default.